Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, ottobre 30
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Anixa Biosciences Inc
ANIX
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$3.30
-0.07
-2.08%
Ult. Agg.: Oct 30, 7:49 AM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Anixa Biosciences Financials
Anixa Biosciences (ANIX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Anixa Biosciences Q3 EPS $(0.08) Beats $(0.09) Estimate, Sales $0.00, Same YoY
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 14.29 percent decrease over losses of $(0.07) per share
Benzinga Newsdesk
PRO
Anixa Biosciences Q2 EPS $(0.07) Beats $(0.09) Estimate
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 22.22 percent increase over losses of $(0.09) per share from
Benzinga Newsdesk
PRO
Anixa Biosciences Q3 EPS $(0.07) Beats $(0.09) Estimate
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 19.54 percent. This is a 30 percent increase over losses of $(0.10) per share from
Benzinga Newsdesk
PRO
Anixa Biosciences Highlights 2024 Achievements And 2025 Goals: Utilized $7M, Ended With $20M Cash, Presented Phase 1 Breast Cancer Vaccine Data With 70% Immune Response, Advanced Ovarian Cancer CAR-T Program, Preparing Phase 2 Study And Broader Cancer Vaccine Development
Benzinga Newsdesk
Recap: Anixa Biosciences Q1 Earnings
Benzinga Insights
Mid-Afternoon Market Update: Nasdaq Tumbles 150 Points; Knoll Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.41% to 34,060.60 while the NASDAQ fell 1.08% to 13,900.17. The S&P also fell, dropping 0.59% to 4,160.89.
Lisa Levin
